RT Journal Article SR Electronic T1 Lactobacillus brevis CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1935 OP 1942 DO 10.21873/anticanres.13303 VO 39 IS 4 A1 VITALIANA DE SANCTIS A1 LILIANA BELGIOIA A1 DOMENICO CANTE A1 MARIA R. LA PORTA A1 ORIETTA CASPIANI A1 ROBERTA GUARNACCIA A1 ANGELA ARGENONE A1 PAOLO MUTO A1 DANIELA MUSIO A1 FRANCESCA DE FELICE A1 FRANCESCA MAURIZI A1 FEISAL BUNKHELIA A1 MARIA G. RUO REDDA A1 ALESSIA REALI A1 MAURIZIO VALERIANI A1 MATTIA F. OSTI A1 DANIELA ALTERIO A1 ALMALINA BACIGALUPO A1 ELVIO G. RUSSI YR 2019 UL http://ar.iiarjournals.org/content/39/4/1935.abstract AB Background: Oropharyngeal mucositis occurs in virtually all patients with head and neck cancer receiving radiochemotherapy. The manipulation of the oral cavity microbiota represents an intriguing and challenging target. Patients and Methods: A total of 75 patients were enrolled to receive Lactobacillus brevis CD2 lozenges or oral care regimen with sodium bicarbonate mouthwashes. The primary endpoint was the incidence of grade 3 or 4 oropharyngeal mucositis during radiotherapy treatment. Results: There was no statistical difference in the incidence of grade 3-4 oropharyngeal mucositis between the intervention and control groups (40.6% vs. 41.6% respectively, p=0.974). The incidence of pain, dysphagia, body weight loss and quality of life were not different between the experimental and standard arm. Conclusion: Our study was not able to demonstrate the efficacy of L. brevis CD2 lozenges in preventing radiation-induced mucositis in patients with head and neck cancer. Although modulating homeostasis of the salivary microbiota in the oral cavity seems attractive, it clearly needs further study.